belantamab mafodotin
1 product
11 abstracts
Abstract
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).Org: Princess Margaret Cancer Centre, Ankara University, University Hospital Brno, General Hospital Evangelismos, Athens, Greece, St. Vincent's Hospital Melbourne,
Abstract
Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire.Org: Health Data Specialists,
Abstract
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).Org: Clinica São Germano, São Paulo, Brazil, Medical University of Lodz, Lodz, Poland, Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland, The First Affiliated Hospital of Soochow University, Suzhou, China, Gorodskaya Klinicheskaya Bol'nitsa Im. Botkina, Moscow, Russian Federation,
Abstract
Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.Org: Yale School of Public Health, Yale University Shool of Medicine,
Abstract
A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.Org: Memorial Sloan Kettering Cancer Center, Katedra i Klinika Hematoonkologii i Transplantacji Szpiku, Seoul National University Hospital, Hospital Quirón Madrid, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.Org: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Dublin, Ireland, Alexandra Hospital, Athens, Greece,
Abstract
A matching-adjusted indirect treatment comparison of elranatamab in patients with triple-class exposed relapsed/refractory multiple myeloma: Comparisons with belantamab mafodotin, selinexor plus dexamethasone, and real-world physician’s choice of treatment.Org: Pfizer Inc., London, United Kingdom, Cytelligen, San Diego, CA,
Abstract
Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.Org: Cerner Enviza, Pfizer Inc., London, United Kingdom,
Abstract
Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.Org: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Dublin, Ireland, Alexandra Hospital, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Alexandra Hospital, Athens, Greece,
Abstract
Clinical outcomes of patients with multiple myeloma following disease progression after BCMA-targeted CAR T-cell therapy.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, UT Health Sciences Center at Houston, University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.Org: Vanderbilt University Medical Center, Hematology Department, Hospital Universitari i Politècnic La Fe, CHU Nantes-Department of Hepato-Gastroenterology, University of North Carolina School of Medicine, University of Wisconsin Health,
Product
Belamaf